Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Excluding Breast Cancer”

13 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 13 results

Early research (Phase 1)Study completedNCT01874522
What this trial is testing

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

Who this might be right for
Advanced Solid Tumors (Excluding Breast Cancer)
Taiho Oncology, Inc. 46
Testing effectiveness (Phase 2)Looking for participantsNCT06380816
What this trial is testing

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Who this might be right for
Advanced Solid TumoursSquamous Cell Carcinoma of Head and NeckCarcinoma, Non-Small-Cell Lung+8 more
Cancer Research UK 167
Early research (Phase 1)Study completedNCT03752398
What this trial is testing

XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

Who this might be right for
Melanoma (Excluding Uveal Melanoma)Cervical CarcinomaPancreatic Carcinoma+13 more
Xencor, Inc. 198
Not applicableLooking for participantsNCT05042687
What this trial is testing

Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 300
Early research (Phase 1)Study completedNCT01596647
What this trial is testing

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors, Excluding Breast Cancer
Novartis Pharmaceuticals 39
Early research (Phase 1)Study completedNCT01700270
What this trial is testing

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.

Who this might be right for
Advanced Solid Tumors, Excluding Breast Cancer
Novartis Pharmaceuticals 45
Testing effectiveness (Phase 2)Looking for participantsNCT06271837
What this trial is testing

T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

Who this might be right for
Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
AstraZeneca 175
Early research (Phase 1)Study completedNCT05585034
What this trial is testing

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Who this might be right for
Head and Neck Squamous Cell CarcinomaMelanoma Excluding Uveal MelanomaNon-small Cell Lung Cancer, Squamous or Non-squamous+6 more
Xencor, Inc. 60
Early research (Phase 1)Study completedNCT01867866
What this trial is testing

Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone

Who this might be right for
Advanced Solid Tumors
Taiho Oncology, Inc. 44
Large-scale testing (Phase 3)Study completedNCT00330759
What this trial is testing

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

Who this might be right for
Bone Metastases
Amgen 1,779
Early research (Phase 1)Study completedNCT01867879
What this trial is testing

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors (Excluding Breast Cancer)
Taiho Oncology, Inc. 44
Early research (Phase 1)Study completedNCT01421004
What this trial is testing

Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsExcluding Breast Cancer
Novartis Pharmaceuticals 166
Testing effectiveness (Phase 2)Active Not RecruitingNCT04482309
What this trial is testing

T-DXd in Patients With Selected HER2 Expressing Tumors

Who this might be right for
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal CancerPart 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca 477